Study S001124

Efficacy and Safety of Early Initiation of Oral Semaglutide 50 mg Once Daily Versus Empagliflozin 25 mg Once Daily in Younger Patients With Newly Diagnosed Type 2 Diabetes and Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05444153
Acronym: PIONEER START
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: WITHDRAWN
Enrollment: 0
Start: 2022-10-06
Primary completion: 2024-10-02
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide; DRUG:Empagliflozin
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1270-0763; EUDRACT_NUMBER:2021-005396-39

Registered primary outcomes

Participants acheiving glycated haemoglobin (HbA1c) less than (<) 7 percentage (%) (Yes/No) [At week 104]
Participants acheiving body weight reduction greater than or equal to (>=) 5% (Yes/No) [At week 104]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.